https://www.jnj.com/media-center/press-releases/janssen-presents-initial-results-for-bcma-car-t-therapy-jnj-4528-showing-early-deep-and-high-responses-in-the-treatment-of-relapsed-or-refractory-multiple-myeloma
Results from Phase 1b/2 CARTITUDE-1 to premiere in oral presentation at ASH 2019 (Abstract #577)
janssenpresentsinitialresultsbcma
https://org.thebcma.com/
The BC Muslim Association - Branches and Chapters
bcmarichmondbranch
https://www.pharmaceutical-technology.com/data-insights/bcma-cd19-icell-gene-therapeutics-systemic-lupus-erythematosus-likelihood-of-approval/
BCMA-CD19 is under clinical development by iCell Gene Therapeutics and currently in Phase I for Systemic Lupus Erythematosus.
systemic lupus erythematosusbcmagenetherapeutics
https://pubmed.ncbi.nlm.nih.gov/41349540/
Chimeric antigen receptor (CAR) T cell therapies targeting B cell maturation antigen (BCMA) are transforming treatment for relapsed or refractory multiple...
single celllongitudinalatlaspredictoutcome
https://www.mdanderson.org/cancerwise/your-questions-about-bcma-and-multiple-myeloma--answered.h00-159619434.html
BCMA stands for B cell maturation antigen, and it's emerged as an important target in multiple myeloma.
multiple myelomamd andersonquestionsbcmaanswered
https://www.bcmakorea.com/
International Montessori Academy
bcma